FDA Gives Orphan Drug Status to AstraZeneca, Merck & Co.'s Lynparza
October 16 2018 - 02:51AM
Dow Jones News
By Carlo Martuscelli
The U.S. Food & Drug Administration has granted orphan drug
designation tp AstraZeneca PLC's (AZN.LN) and Merck & Co.
Inc.'s (MRK) Lynparza to treat pancreatic cancer, Astra said
Tuesday.
Orphan drug designation is given to medicines that aim to treat
rare diseases and provides benefits such as market exclusivity and
tax breaks. Lynparza was previously granted orphan drug status for
ovarian cancer, as well as fallopian tube and primary peritoneal
cancer.
Lynparza is being developed by AstraZeneca and Merck & Co.
as part of a strategic collaboration in the field of oncology. It
is currently undergoing a phase 3 trial, with results expected in
the first half of 2019.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 16, 2018 02:36 ET (06:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024